Roxane announces FDA approval for Anastrozole Tablets ANDA

Jul 9 2010NewsGuard 100/100 Score

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the U.S. Food and Drug Administration.  The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.  Annual sales of ARIMIDEX® are approximately $916.8 Million(1). ARIMIDEX® (anastrozole) is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer; First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer; treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Source:

Roxane Laboratories, Inc.

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Study reveals how cancer cells evade chemotherapy in low-glucose environments
Rare genetic mutations in healthy women may be key to breast cancer origins
History of endometriosis and fibroids linked to higher long-term risk of early death
Study shows AI can predict prognosis in triple-negative breast cancer
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation
Golgi apparatus plays crucial role in enhancing T-cell function against cancer
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients
Hormone therapy and puberty blockers alter skeletal size in transgender individuals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Researchers uncover key genes linked to DCIS progression